ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Adverse events"

  • Abstract Number: 2178 • 2016 ACR/ARHP Annual Meeting

    Statin Use and Increased Risk of Musculoskeletal Conditions: A Retrospective Cohort Study with Propensity Score-Matching

    Una E. Makris1,2, Carlos A. Alvarez2,3,4, Eric M. Mortensen2,4 and Ishak Mansi2,4, 1Rheumatology, UT Southwestern Medical Center, Dallas, TX, 2VA North Texas Health Care System, Dallas, TX, 3Texas Tech University Health Science Center, Dallas, TX, 4UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: Given conflicting evidence regarding statin use and the relationship with musculoskeletal conditions, and the rising disability and societal/personal repercussions associated with both osteoarthritis (OA)…
  • Abstract Number: 2332 • 2016 ACR/ARHP Annual Meeting

    Midterm Outcome of Modular Metal-on-Metal Total Hip Arthroplasty

    Hiroki Wakabayashi1, Masahiro Hasegawa2, Toshio Yamaguchi3, Yohei Naito4 and Akihiro Sudo5, 1Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Japan, 2Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, 3Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan, 4Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Mie, Japan, 5Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan

    Background/Purpose:  Wear, osteolysis, and late aseptic loosening associated with ultrahigh-molecular-weight polyethylene components used in total hip arthroplasties (THA) have led to increased interest in metal-on-metal…
  • Abstract Number: 2444 • 2016 ACR/ARHP Annual Meeting

    Effects of Disease Activity and Drug Exposure on Pregnancy Outcomes with Inflammatory Arthritis

    Emily Fishman1, Kathryn H. Dao2 and John J. Cush3, 1Texas A&M HSC College of Medicine, Dallas, TX, 2Texas Health, Dallas, TX, 3Baylor Research Institute, Dallas, TX

    Background/Purpose: Pregnancy is often encountered in women who have inflammatory arthritis (IA), such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile arthritis (JIA) or ankylosing…
  • Abstract Number: 2547 • 2016 ACR/ARHP Annual Meeting

    Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis

    Frank Buttgereit1, Jonna Amann2, Friederike Breitenfeldt3, Dörte Huscher4, Johannes WJ Bijlsma5 and Johannes WG Jacobs6, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 3Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, 4Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, 5ARC, Amsterdam, Netherlands, 6Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Glucocorticoids (GCs) are frequently and often chronically used for the treatment of rheumatoid arthritis (RA) and other immune diseases and vasculitis. An estimated 0.8–1.2%…
  • Abstract Number: 2595 • 2016 ACR/ARHP Annual Meeting

    Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry

    Arthur F. Kavanaugh1, Jamie Geier2, Clifton Bingham III3, Connie Chen2, George W. Reed4,5, Katherine C. Saunders4, Yan Chen6, Andrew Koenig6, Laura Cappelli7, Jeffrey D. Greenberg4,8 and Joel M. Kremer9, 1University of California, San Diego School of Medicine, LaJolla, CA, 2Pfizer, Inc., New York, NY, 3Johns Hopkins University, Baltimore, MD, 4Corrona, LLC, Southborough, MA, 5University of Massachusetts Medical School, Worcester, MA, 6Pfizer, Inc., Collegeville, PA, 7Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, 8NYU School of Medicine, New York, NY, 9Albany Medical College and the Center for Rheumatology, Albany, NY

    Background/Purpose: An interim analysis of a prospective observational 3+ year study, embedded within the US Corrona Rheumatoid Arthritis (RA) registry (14 years and ongoing), was…
  • Abstract Number: 2629 • 2016 ACR/ARHP Annual Meeting

    Serious Adverse Events in Patients with RA Taking Abatacept Compared with Other Dmards. Results from a US-Wide Safety Registry

    Kaleb Michaud1,2, Sofia Pedro2, TA Simon3, Frederick Wolfe2 and Rebecca Schumacher2, 1University of Nebraska Medical Center, Omaha, NE, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Observational studies are critical in assessing medication safety and effectiveness in the real world. Nonrandom assignment can provide insight to how and when medications…
  • Abstract Number: 2970 • 2016 ACR/ARHP Annual Meeting

    Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database

    Bertrand Lioger1,2, Fanny Hennekinne1, Marie-Sara Agier3, Annie-Pierre Jonville-Bera3,4 and François Maillot1,5, 1Internal Medicine, Tours University Hospital, Tours, France, 2GICC UMR 7292, University François Rabelais, Tours, France, 3Clinical Pharmacology, Tours University Hospital, Tours, France, 4Regional Pharmacovigilance Center, Tours University Hospital, Tours, France, 5INSERM U1069, University François Rabelais, Tours, France

    Background/Purpose: Immunological classes of adverse events (AEs), including the immune related AEs and the paradoxical effects, have emerged with the used of biologics. Among them,…
  • Abstract Number: 3141 • 2016 ACR/ARHP Annual Meeting

    Development of a Glucocorticoid Toxicity Index Using Multi-Criteria Decision Analysis

    Eli Miloslavsky1, Raymond P. Naden2, Johannes WJ Bijlsma3, Paul Brogan4, Sherwood Brown5, Paul Brunetta6, Frank Buttgereit7, Hyon K. Choi8, Jean-Francois Dicaire9, Jeffrey Gelfand10, Liam Heaney11, Liz Lightstone12, Leo Lu13, Dedee Murrell14, Michelle Petri15, James T. Rosenbaum16, Kenneth Saag17, Murray Urowitz18, Kevin L Winthrop19 and John H. Stone20, 1Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, 3ARC, Amsterdam, Netherlands, 4Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 5Psychiatry, UT Southwestern Medical Center, Dallas, TX, 6Genentech, Inc., South San Francisco, CA, 7Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, 8Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 9Pinnacle Inc., Quebec, QC, Canada, 10Neurology, University of California San Francisco, San Francisco, CA, 11Department of Respiratory Medicine, Queen's University Belfast, Belfast, Ireland, 12Department of Medicine, Imperial College London, London, England, 13Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 14Department of Dermatology, University of New South Wales, Sydney, Australia, 15Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, 16Oregon Health & Science University, Portland, OR, 17Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham School of Medicine, Birmingham, AL, 18Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 19Oregon Health and Sciences University, Portland, OR, 20Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Glucocorticoids (GC) are associated with substantial treatment morbidity.  New immunomodulatory agents offer the possibility of limiting GC exposure.  To assess the comparative benefits of…
  • Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting

    Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

    Meghna Jani1, William G Dixon2, Lianne Kearsley-Fleet3, Ian N. Bruce4,5, Hector Chinoy6,7, Anne Barton6,8, Mark Lunt9, Kath Watson3, Deborah P.M. Symmons1, Kimme L. Hyrich3 and on behalf of the BSRBR-RA, 1Centre for Musculoskeletal Research, University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, 2Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 4Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 5Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, 6Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 7NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, 8NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, 9Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom

    Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…
  • Abstract Number: 2157 • 2015 ACR/ARHP Annual Meeting

    Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis

    Matthew J. Koster1, Cristian Labarca2, Cynthia S. Crowson3, Ashima Makol1, Steven R. Ytterberg4, Eric L. Matteson1 and Kenneth J. Warrington1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, 3Health Sciences Research, Mayo Clinic, Rochester, MN, 4Rheumatology Division, Mayo Clinic, Rochester, MN

    Background/Purpose: Relapses in patients with giant cell arteritis (GCA) are common and often lead to higher cumulative use of glucocorticoids. This study aims to evaluate…
  • Abstract Number: 443 • 2015 ACR/ARHP Annual Meeting

    Drug Survival and Reasons for Discontinuation of Biological Disease Modifying Antirheumatic Drug in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization (RDPA) Register

    Pongthorn Narongroeknawin1, Wanruchada Katchamart2, Parawee Suwannalai3, Nuntana Kasitanon4, Tasanee Kitumnuaypong5, Ajanee Mahakkanukrauh6 and Boonjing Siripaitoon7, 1Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand, 2Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj hospital, Mahidol University, Bangkok, Thailand, 3Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 4Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, 5Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital, Bangkok, Thailand, 6Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, 7Division of Rheumatology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand

    Background/Purpose: To evaluate long-term efficacy and safety of biological disease modifying antirheumatic drug (bDMARD) in real-life practice and identify risk factors related to remission and drug discontinuation…
  • Abstract Number: 2167 • 2015 ACR/ARHP Annual Meeting

    Application of Combined Reporting of Benefit and Harm (OMERACT 3×3 methodology) to the Rheumatoid Arthritis Comparison of Active Therapies Trial

    Maarten Boers1,2, Sarah Leatherman3, James R. O'Dell4 and Jeffrey R. Curtis5, 1Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands, 3MAVERIC CSPCC (151MAV), VA Boston Healthcare System, Boston, MA, 4University of Nebraska Medical Center, Omaha, NE, 5Birmingham VAMC, Birmingham, AL

    Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Initiative has suggested an analysis of the occurrence of benefit and harm in trials simultaneously, at the individual…
  • Abstract Number: 464 • 2015 ACR/ARHP Annual Meeting

    Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis

    Cheryl Barnabe1, Yufei Zheng2, Arto Ohinmaa2, Brenda Hemmelgarn3, Gilaad Kaplan4, Liam Martin5 and Walter Maksymowych6, 1Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2Institute of Health Economics, Edmonton, AB, Canada, 3Division of Nephrology, University of Calgary, Calgary, AB, Canada, 4Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, 5Medicine, University of Calgary, Calgary, AB, Canada, 6Medicine, Medicine, University of Alberta, Edmonton, AB, Canada

    Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis Background/Purpose: Aboriginal people with rheumatoid arthritis (RA) have more severe disease and an…
  • Abstract Number: 552 • 2015 ACR/ARHP Annual Meeting

    The Relationship Between Efficacy and Toxicity in Patients with Rheumatoid Arthritis Receiving Methotrexate in Combination with Adalimumab

    Gerd Burmester1, Gurjit S. Kaeley2, Arthur Kavanaugh3, Cem Gabay4, Daryl MacCarter5, Peter Nash6, Tsutomu Takeuchi7, Anabela Cardoso8, Shufang Liu9, Hartmut Kupper10 and Jasmina Kalabic11, 1Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, 2University of Florida, Jacksonville, FL, 3University of California, San Diego School of Medicine, LaJolla, CA, 4Rheumatology, Geneva University Hospital, Geneva, Switzerland, 5Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, 6Department of Medicine, University of Queensland, Brisbane, Australia, 7Keio University School of Medicine, Tokyo, Japan, 8Torre Oriente, AbbVie, Lisboa, Portugal, 9Immunology Development, AbbVie, North Chicago, IL, 10AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, 11AbbVie, North Chicago, IL

    Background/Purpose: Combination treatment of rheumatoid arthritis (RA) with methotrexate (MTX)+adalimumab (ADA) has been shown to be more effective than ADA monotherapy. However, MTX is associated…
  • Abstract Number: 561 • 2015 ACR/ARHP Annual Meeting

    Improvement in Disease Activity and the Long-Term Risk of Serious Infectious Events in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol

    Jeffrey R. Curtis1, Marc de Longueville2, Cathy O'Brien2 and Boulos Haraoui3, 1University of Alabama at Birmingham, Birmingham, AL, 2UCB Pharma, Brussels, Belgium, 3Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada

    Background/Purpose: Anti-TNF drugs are an effective treatment option for rheumatoid arthritis (RA) patients (pts) but have been associated with an increased incidence of serious infectious…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology